John Parkinson

Although there have been decreases in newly reported chronic hepatitis C cases across many demographics, the need to get people screened and given therapy in the same visit remains vital.

Study shows benefit using antibiotic earlier in clinical care for gram-negative infections.

During these uncertain times, RAIN President and CEO Chelsea Gulden talks about the importance of taking a grassroots approach to HIV advocacy to work with young people in the local communities who are either dealing with the virus or are susceptible to it.

With the Trump administration’s plans to cease funding for Gavi, the Vaccine Alliance, as well as to reduce the US Department of Health and Human Services personnel, public health, both internationally and domestically, is going to be widely affected.

This open-label trial will compare the combination of the company’s therapies, bemnifosbuvir and ruzasvir, with another hepatitis C combination regimen.

Although the TB pipeline has several new agents in various phases, challenges to antimicrobial development remain. Therefore treatment adherence remains paramount.

A new analysis raises concerns over the stoppage of funding for this long-standing program, which could have major impacts on global public health for years to come.

A child who was not vaccinated succumbed to measles pulmonary failure. Additionally, increased cases and hospitalizations continue to grow greatly in the state.

Andrew Aronsohn, MD, associate professor of Medicine, University of Chicago Medical Center, discusses the hepatitis C (HCV) screen and treat plan that looks to utilize a one visit approach to get people tested and on medication in the same patient encounter.

Lumen Bioscience’s LMN-201 was considered safe and well tolerated, and there were no severe dose-related or serious adverse events reported.

Indwelling devices and previous antibiotic exposure increased the risk for these infections.

Ohio is now dealing with an outbreak, and the Centers for Disease Control and Prevention (CDC) reports nearly 500 total cases in the US.

Clinical-stage company, BiomX, said its therapy, BX211, was found to be safe and efficacious for this infection that was associated with Staphylococcus aureus.

The organization's reports discuss the small number of newly approved treatments, the limited, late-stage antifungal pipeline, and challenges around diagnostics for this class of infections.

Tina Tan, MD, FIDSA, FPIDS, FAAP, Infectious Diseases Society of America (IDSA) president, discusses the potential implications these layoffs will have on clinicians and overall public health.

The Visby Medical Women’s Sexual Health Test can screen for chlamydia, gonorrhea, and trichomoniasis.

Pamela Kushner, MD, offers insights on the newly approved antibiotic including its novel mechanism of action, the new criteria incorporated into the phase 3 studies, and what it means for her to have this treatment available.

In the second installment of our interview with Robert Hopkins Jr, MD, the medical director of the National Foundation for Infectious Diseases (NFID), he discusses some of the takeaways in how public health messaging was lost on the public, which lead to mistrust, and thus leaving open the door for disinformation and misinformation.

The study, being conducted by Bluejay Therapeutics, will evaluate the efficacy and safety of its monoclonal antibody, brelovitug (also known as BJT-778), compared to delayed treatment.

Kansas now has an outbreak with at least 10 confirmed cases with an expectation from the state's health officials that there will be more.

This is the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in nearly 30 years.

In the second installment of our COVID-19 pandemic series, Robert Hopkins Jr, MD, the medical director of the National Foundation for Infectious Diseases (NFID), discusses the paradox that has arisen from the COVID-19 vaccines that in spite of their development in record time, what remains is a deeper mistrust in immunizations overall.

Monday is World Tuberculosis (TB) Day, and a vaccine developed by the Gates Medical Research Institute is being studied in a phase 3 trial. If approved, the vaccine could potentially prevent pulmonary TB in adults and adolescents.

Sesh Sundararaman, MD, PhD, discusses his findings and how this approach can be triggered to minimize undesirable treatment features and open the door to newer treatment possibilities.

Examined over a 5-year period, the Jackson Health System in Florida reported large volumes of positive cultures for the fungal infection every year and that infection sources expanded over time.

This is the first in a series on the 5 year anniversary of the pandemic. We want to cover a variety of aspects around it, including lessons learned such as testing, vaccine development, and public health policy as well as some ongoing challenges that remain including vaccine hesitancy and an increase in antimicrobial resistant infections.

A long-term study conducted by the Centers for Disease Control and Prevention (CDC) shows early success in the reduction of such infections followed by an increase again during the early pandemic years. Additionally, certain pathogens overall saw an increase, whereas other infections were stable or saw decreases.

The Peggy Lillis Foundation's (PLF) CEO and Cofounder Christian John Lillis talks about these important events happening in the capital at the end of this month.

Despite a large number of new infections globally, an international survey shows real reservations by people to get screened and limited knowledge about the risks, thus preventing them from seeking needed treatment.

The vaccine is based on an attenuated rabies vaccine that was subsequently inactivated to make the vaccine candidate. The National Institutes of Health (NIH) is sponsoring the trial.